Stevenage Bioscience Catalyst (SBC) is pleased to announce that Dr Wesley Randle is to join as Chief Business Officer (CBO) in June 2019.
Dr Randle joins from UCLB, the technology transfer company of UCL and its partner NHS Trusts where he was a Senior Business Manager. Whilst at UCLB he worked closely with the UCL Technology Fund and was responsible for managing the commercialisation of IP and technology at UCL Institute of Ophthalmology and Moorfields Eye Hospital.
Prior to joining UCLB, Wesley worked in a number of early stage companies including an Imperial College regenerative medicine…
Funds will accelerate commercialization of InVisionFirstTM-Lung Liquid Biopsy test and the development of the InVision® liquid biopsy platform into new indications
Research Triangle Park, NC and Cambridge, UK, March 28, 2019 -- Inivata, a leader in liquid biopsy, today announces the completion of a Series B fundraising of $52.6m (£39.8 million).
Existing investors Woodford Patient Capital Trust, IP Group, Cambridge Innovation Capital and Johnson & Johnson Innovation – JJDC all participated in the round alongside new investor RT Ventures. The first close of the financing occurred in August…
Basel (CH) 27 March 2019 – Lonza announced today the next stage in the evolution of its market-leading GS Xceed® expression platform with the launch of GS piggyBac™, a highly efficient gene integration technology. GS piggyBac™ is capable of inserting large DNA cargos into transcriptionally active and genetically stable areas of the genome associated with highly expressed genes. Demonstrating higher yields and enhanced performance, GS piggyBac™ is well suited to support the expression of challenging proteins.
Commitment to innovation
Lonza’s GS Xceed® expression system is…
NICE issues Medtech Innovation Briefing on PredictSURE IBD™ for inflammatory bowel disease prognosis
Cambridge, UK, 28 March 2019: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced that the UK's National Institute for Health and Care Excellence (NICE) has published a Medtech Innovation Briefing (MIB) on the use of PredictSURE IBD™ in the prognosis of inflammatory bowel disease.
MIBs are NICE advice designed to support NHS and social care commissioners and staff who are considering using new medical devices and other medical or diagnostic technologies. Designed to be fast, flexible…
BioIVT will contribute its assay development and validation expertise to support the consortium’s research initiatives
Westbury, NY – Mar. 25, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has joined the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium.
The FNIH Biomarkers Consortium is a public-private biomedical research partnership. It brings together members of industry, academia, nonprofit and patient advocacy organizations, and government agencies and institutes to…
Cambridge, UK, 25 March 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced it is collaborating with St George’s University Hospital, London, and the European Molecular Genetics Quality Network (EMQN), based within the Manchester Centre for Genomic Medicine at Saint Mary’s Hospital, to develop reference material for non-invasive prenatal testing (NIPT).
Well-characterized reference material that consists of matched (related) maternal and fetal DNA with a variety of chromosomal aneuploidies…
The 10th annual Babraham Investor Conference is taking place in Cambridge on 15 May 2019
Babraham 25th March 2018: Now in its 10th year, the one-day Babraham Investor Conference (BIC) will bring together like-minded investors focused on early-stage and scale-up life science and med-tech opportunities across the UK and Europe.
As well as expert-led panel discussions and sessions focused on scale-up and venture-stage growth companies, investors will hear pitches from a broad spectrum of early stage and scale-up companies seeking investment.
Taking place at the Babraham Research Campus, the…
The AMR Centre, a body with public and private investors leading the UK’s response to the global health threat posed by antimicrobial resistance, has received a significant funding package to support the expansion of its pipeline of new drugs to treat drug-resistant infections.
The package totals £2.3m and is led by an investment from LifeArc, one of the UK’s foremost medical research charities. Other backers include Bruntwood SciTech, MGL, and the Greater Manchester and Cheshire Life Sciences Fund.
Based at Alderley Park, Cheshire, the AMR Centre is focused on accelerating the development of…
Developers of pioneering prognostic tools recognised for its innovative product development and contribution to life science discovery
Cambridge, UK, 21 April 2019: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, are delighted to have been awarded the Life Science Innovation award for product development at the annual Business Weekly awards.
Held annually, The Business Weekly awards reflect the successful and fast-paced nature of the innovation cluster in the East of England. World-class and…
Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that a Phase I Clinical Trial Application (“CTA”) for product candidate AT247 has been approved by the Bundesamt für Sicherheit im Gesundheitswesen (BASG), the Austrian Federal Office for Safety in Health Care.
Arecor’s AT247, is an ultra-rapid acting prandial insulin product candidate targeting improved treatment for people living with Type I diabetes. Prandial insulin is used…